ストックスクリーナーアプリを入手
15.73
2.36%
-0.38
アフターアワーズ：
15.73
Novocure Ltd (NVCR) 最新ニュース
Can Novocure's PANOVA-3 Trial Of TTFields Therapy Electrify The Stock? - RTTNews
NovoCure Limited (NASDAQ:NVCR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
NovoCure (NVCR) Shares Cross Below 200 DMA - Nasdaq
NovoCure Ltd (NVCR) Trading Down 2.79% on Nov 14 - GuruFocus.com
Baillie Gifford & Co. Sells 28,207 Shares of NovoCure Limited (NASDAQ:NVCR) - MarketBeat
Analyze NovoCure Ltd (NASDAQ: NVCR) Before Investing. - Stocks Register
Nordwand Advisors LLC Buys 1,514,824 Shares of NovoCure Limited (NASDAQ:NVCR) - MarketBeat
NovoCure Ltd (NVCR) Shares Up 3.63% on Nov 8 - GuruFocus.com
Novocure's oncology president sells $9,530 in shares - Investing.com India
Novocure's COO Mukund sells shares worth $2,540 By Investing.com - Investing.com Canada
Novocure's COO Mukund sells shares worth $2,540 - Investing.com India
Michal Nath Puri Sells 810 Shares of NovoCure Limited (NASDAQ:NVCR) Stock - MarketBeat
Novocure's oncology president sells $9,530 in shares By Investing.com - Investing.com Australia
NovoCure Ltd (NVCR) Shares Up 3.96% on Nov 4 - GuruFocus.com
FY2024 EPS Estimates for NovoCure Lifted by HC Wainwright - MarketBeat
Analyst Estimates: Here's What Brokers Think Of NovoCure Limited (NASDAQ:NVCR) After Its Third-Quarter Report - Simply Wall St
NovoCure Limited (NASDAQ:NVCR) Q3 2024 Earnings Call Transcript - Insider Monkey
NovoCure shares hold Buy rating, steady price target post-earnings - Investing.com
NovoCure shares hold Buy rating, steady price target post-earnings By Investing.com - Investing.com UK
NovoCure's (NVCR) Buy Rating Reiterated at HC Wainwright - MarketBeat
NovoCure’s Strong Q3 and Leadership Changes in 2024 - Yahoo Finance
NovoCure: Q3 Earnings Snapshot - Milford Mirror
NovoCure Ltd (NVCR) Q3 2024 Earnings Call Highlights: Strong Rev - GuruFocus.com
NovoCure Ltd (NVCR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ... - Yahoo Finance
Novocure names Christoph Brackmann as new CFO - Investing.com India
Novocure’s Q3 2024 Results Highlight Growth and Innovation - TipRanks
NovoCure (NASDAQ:NVCR) Stock Price Down 7.1%Should You Sell? - MarketBeat
Novocure Ltd earnings beat by $0.05, revenue topped estimates - Investing.com
NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Novocure Appoints Christoph Brackmann as Chief Financial Officer - Yahoo Finance
Novocure Reports Third Quarter 2024 Financial Results - Yahoo Finance
Semanteon Capital Management LP Makes New Investment in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
NovoCure (NVCR) Set to Announce Quarterly Earnings on Wednesday - MarketBeat
Brokerages Set NovoCure Limited (NASDAQ:NVCR) PT at $26.17 - MarketBeat
NovoCure Limited (NASDAQ:NVCR) Shares Sold by SG Americas Securities LLC - MarketBeat
Novocure shares soar 33% as FDA approves lung cancer treatment - MSN
Leerink Partnrs Forecasts Stronger Earnings for NovoCure - MarketBeat
NovoCure scoops FDA approval on wearable for metastatic cancer treatment - Medical Device Network
Novocure's Optune Lua Receives FDA Approval For Lung Cancer Treatment - Yahoo Finance
Novocure scoops FDA approval for electric field lung cancer treatment device - Mugglehead
Deep Dive Into NovoCure Stock: Analyst Perspectives (4 Ratings) - Benzinga
NovoCure Ltd (NVCR) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - The InvestChronicle
NovoCure (NASDAQ:NVCR) Shares Gap UpTime to Buy? - MarketBeat
Novocure wins FDA approval for electric field device in lung cancer - BioPharma Dive
A new trading data show NovoCure Ltd (NVCR) is showing positive returns. - SETE News
NovoCure Ltd (NVCR)’s Market Momentum: Closing Strong at 17.78, Up 10.71 - The Dwinnex
NovoCure: There Is Still More Upside (Rating Upgrade) (NASDAQ:NVCR) - Seeking Alpha
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages NovoCure Limited Investors to Secure Counsel Before Important Deadline in Securities Class ActionNVCR - AsiaOne
NovoCure stock upgraded to buy, price target set on recent FDA approval - Investing.com
NovoCure stock upgraded to buy, price target set on recent FDA approval By Investing.com - Investing.com South Africa
NovoCure (NASDAQ:NVCR) Rating Increased to Buy at HC Wainwright - MarketBeat
1.38%
0.43%
大文字化:
|
ボリューム (24 時間):